NVX-207

NVX-207, a Betulinic acid-derived anti-cancer compound, shows anti-tumor activity (mean IC50=3.5 μM) against various human and canine cell lines. NVX-207-induced apoptosis is associated with activation of the intrinsic apoptotic pathway via cleavage of caspases -9, -3, -7 and of PARP[1].

Product Specifications

CAS Number

[745020-66-0]

UNSPSC

12352211

Target

Apoptosis

Type

Reference compound

Related Pathways

Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/NVX-207.html

Concentration

10mM

Purity

98.0

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C([C@]1(CC[C@H]2C(C)=C)[C@@]2([H])[C@](CC[C@@]3([H])[C@]4(CC[C@]5([H])[C@@]3(CC[C@H](OC(C)=O)C5(C)C)C)C)([H])[C@@]4(C)CC1)OCC(CO)(N)CO

Molecular Formula

C36H59NO6

Molecular Weight

601.86

References & Citations

[1]Willmann M, et al. Characterization of NVX-207, a novel betulinic acid-derived anti-cancer compound. Eur J Clin Invest. 2009;39 (5) :384-394.|[2]Bache M, et al. Betulinic acid derivatives NVX-207 and B10 for treatment of glioblastoma--an in vitro study of cytotoxicity and radiosensitization. Int J Mol Sci. 2014 Oct 30;15 (11) :19777-90.